首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   183篇
  完全免费   111篇
  眼科学   294篇
  2020年   6篇
  2019年   12篇
  2018年   35篇
  2017年   28篇
  2016年   33篇
  2015年   18篇
  2014年   25篇
  2013年   10篇
  2012年   20篇
  2011年   25篇
  2010年   16篇
  2009年   15篇
  2008年   16篇
  2007年   15篇
  2006年   5篇
  2005年   3篇
  2002年   1篇
  1998年   3篇
  1995年   1篇
  1994年   1篇
  1993年   1篇
  1991年   1篇
  1988年   2篇
  1980年   1篇
  1975年   1篇
排序方式: 共有294条查询结果,搜索用时 36 毫秒
1.
姜黄素兔眼玻璃体内注射后眼内毒副作用研究   总被引:4,自引:0,他引:4  
目的研究不同剂量姜黄素兔眼玻璃体内注射后的眼内毒副作用。方法40只实验兔,随机分为4组,每组10只,一眼为实验眼,玻璃体内分别注射0.05mg/0.1ml、0.1mg,0.1ml、0.2mg,0.1ml姜黄素及0.5‰的DMSO 0.1ml;对侧眼为对照眼,在玻璃体内注射0.1ml生理盐水注射后于第1、第3、第7、第14天进行常规眼部检查和视网膜电图检查:在第3、第7、第14天分别摘取2只眼球做光学和透射电子显微镜检查。结果0.2mg组在注药后第3天和第7天,实验眼暗适应视网膜电图a波振幅分别为(129±9)μV和(131±11)μV,与对照眼的(145+13)μV和(146+11)μV相比显著降低(P〈0.01);实验眼b渡振幅分别为(259±9)μV和(257±7)μV,与对照眼的(283±13)μ V和(276+8)μV相比显著降低(P〈0.01)。第14天时a波和b波振幅又恢复正常,其余各组各时间段,实验眼a波和b波振幅与对照眼相比差异无统计学意义。各时间段常规眼部检查和视网膜组织学栓查正常。结论 姜黄素玻璃体内注射0.2mg以下剂量是安全可行的。  相似文献
2.
玻璃体切割联合眼内注药治疗感染性眼内炎   总被引:4,自引:0,他引:4  
目的观察玻璃体切割联合眼内注药治疗感染性眼内炎的疗效。方法回顾分析2005年5月至2007年1月收治的6例严重眼内炎行玻璃体切割联合眼内注药,4例眼内异物摘除,硅油填充治疗,观察术后的感染控制情况及视功能。结果手术后6例炎症得到控制,5例视力不同程度提高,1例眼球萎缩。结论玻璃体切割配合眼内注药是治疗感染性眼内炎的有效手段。  相似文献
3.
曲安奈德玻璃体腔注射治疗黄斑水肿的临床观察   总被引:4,自引:4,他引:0  
李鹏  王莉  高丹宇 《国际眼科杂志》2007,7(6):1720-1721
目的:观察曲安奈德(triarncinolone acetonide,TA)玻璃体腔注射治疗黄斑水肿(maeular edema,ME)的疗效。方法:对22例(26眼)黄斑水肿患者行玻璃体腔内注射曲安奈德后定期随访3a,观察治疗前后视力、眼压及眼底黄斑区改变情况。结果:全部患者玻璃体腔内注射曲安奈德后视力比术前提高,黄斑水肿消退或减轻。结论:玻璃体腔内注射曲安奈德可消除黄斑水肿,提高视力,但远期效果有待进一步研究。  相似文献
4.
目的评价白内障超声乳化吸除及人工晶状体植入术中玻璃体腔内注射曲安奈德(TA)对伴有糖尿病黄斑水肿的白内障患者的疗效及安全性。方法 25例合并糖尿病黄斑水肿的白内障患者随机分为注药组、对照组,均采用标准的超声乳化白内障吸除及人工晶状体植入术。注药组13例患者术毕时,玻璃体腔内注射TA 4 mg/0.1 m L;对照组12例患者未进行玻璃体药物注射治疗。术后随访1~3个月,观察手术前、后(45±10)d的视力、黄斑中心凹视网膜厚度、眼压及并发症。结果所有患者术后视力较术前皆有提高,但仅有注药组视力改善与术前差异有统计学意义(P<0.05)。注药组术后视力优于对照组,差异有统计学意义(P<0.05)。术前和术后(45±10)d黄斑中心厚度:注药组术前比术后明显下降,差异有统计学意义(P<0.05)。注药组术后黄斑厚度明显低于对照组,差异有统计学意义(P<0.05)。对照组术后比术前视网膜厚度有所增加,差异无统计学意义(P>0.05)。2组间眼压差异无统计学意义(P>0.05);2组皆未观察到严重术后并发症。结论白内障超声乳化及人工晶体植入术中联合TA玻璃体腔注射术能够明显提高患者视力,减轻黄斑水肿,为后续观察和治疗创造条件。  相似文献
5.
目的:探讨玻璃体腔内注射膨胀气体在失败外垫压视网膜脱离手术后的单独应用价值以及手术干预的时机和前提。方法:回顾分析3例3眼接受巩膜外冷凝外垫压失败患者的临床资料,均因原裂孔没有完全封闭致使视网膜不能完全复位,术后72h均实施了单纯的经睫状体平坦部注射膨胀气体手术。结果:单纯玻璃体腔内注气后原视网膜裂孔闭合,视网膜复位,无任何短期和长期并发症的发生。结论:膨胀气体可单独应用在失败的巩膜外垫压术后,该手术较其他任何拟采取的补救措施具有手术时间短、创伤小、费用低、患者易接受等优点。  相似文献
6.
康柏西普联合多种方法综合治疗新生血管性青光眼   总被引:3,自引:3,他引:0       下载免费PDF全文
目的:观察康柏西普联合全视网膜光凝术和复合式小梁切除术综合治疗新生血管性青光眼的临床效果。

方法:对11例11眼新生血管性青光眼患者行康柏西普玻璃体腔注射,观察房角及虹膜新生血管消退后,行复合式小梁切除术,所有患者均在合适的时机行全视网膜光凝术。术后平均随防6mo,观察术后视力、眼压及并发症等情况。

结果:术后眼压与术前比较,术后1wk,1、3、6mo眼压均有下降,且差异有统计学意义(P<0.01)。术后6mo,2眼(18%)矫正视力提高,8眼(73%)视力无明显变化,1眼(9%)视力降低。术后并发症主要包括前房积血、浅前房、玻璃体积血等。

结论:康柏西普玻璃体腔注射联合全视网膜光凝术和复合式小梁切除术综合治疗新生血管性青光眼能有效控制眼压,保护视功能。  相似文献

7.
目的:探讨术前玻璃体腔注射曲安奈德对微创玻璃体切割术治疗脉络膜脱离型视网膜脱离的临床疗效.方法:选择我院2015-01/2016-06临床确诊的脉络膜脱离型视网膜脱离患者23例23眼,入院后先行玻璃体腔内注射曲安奈德4~5 d后行23 G玻璃体切割和硅油填充术.观察手术前后视力、眼压情况,以及术后视网膜复位率和并发症情况.随诊6~9 mo.结果:曲安奈德注射后前房反应均减轻,眼压升高,由入院眼压4.02±1.47mmHg升高到术前13.69±4.68mmHg,术后升高到17.72±5.88mmHg,入院时眼压与术前和术后比较,差异均有统计学意义(P<0.05).患者术后末次随访视力较术前均有所改善,视力术后≥0.3者9眼(39%),术后≥0.05者18眼(78%).术后1wk,1、3mo和末次随访矫正视力与术前比较,差异均有统计学意义(P<0.05).视网膜复位情况:手术后2 wk有23眼(100%)全视网膜在位,一次视网膜解剖复位率87%,二次视网膜解剖复位率100%.术后1 mo时3眼出现下方视网膜局限性脱离,经二次手术巩膜外垫压后视网膜复位.无眼内出血、医源性视网膜裂孔、眼内感染、晶状体损伤等并发症.术后一过性高眼压7眼,均出现在术后12~14d,减少局部激素滴眼液使用和点用降眼压滴眼液后,眼压控制在正常范围.结论:术前玻璃体腔注射曲安奈德进行预手术处理,能够提高微创玻璃体切割术治疗脉络膜脱离型视网膜脱离的疗效,降低手术难度,提高视力,避免了全身使用激素的副作用.  相似文献
8.
Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit   总被引:2,自引:2,他引:0  
Purpose To evaluate the ocular toxicity of escalating doses of intravitreous adalimumab (Humira) in the rabbit eye. Methods Twelve New Zealand albino rabbits received unilateral intravitreous injections of 0.1 ml of adalimumab 0.25 mg (three eyes), 0.50 mg (three eyes), 1.0 mg (three eyes) or 0.1 ml balanced salt solution (BSS, threeeyes). Slit-lamp biomicroscopy and fundoscopy were carried out at baseline, day 1, 7 and 14 following intravitreous injection, while electroretinography (ERG) was carried out at baseline and day 14. Animals were euthanized on day 14, and histopathological examination of the eyes was performed. Results Slit-lamp biomicroscopy and fundoscopy were normal in eyes having received BSS, 0.25 mg or 0.50 mg adalimumab; however, inflammation was present in two of three eyes having received 1.0 mg adalimumab. Similarly, comparison of scotopic and photopic ERG light at baseline and day 14 demonstrated no changes in eyes receiving BSS, 0.25 mg or 0.50 mg adalimumab, but two of three eyes having received 1.0 mg adalimumab showed a greater than 30% reduction in a and b wave. Finally, histopathology demonstrated no differences between eyes receiving BSS, 0.25 mg or 0.50 mg of adalimumab, but two of three eyes injected with 1.0 mg demonstrated inflammatory cell infiltration of the vitreous and anterior chamber, with one of these eyes demonstrating retinal necrosis. Conclusions Escalating doses of intravitreous adalimumab in rabbit eyes caused no detectable functional or structural ocular toxicity up to a dose of 0.50 mg. Administration of 1.0 mg in 0.1 ml was associated with an inflammatory reaction and retinal necrosis. None of the authors has any proprietary interest in any technique or product described herein. The authors have full control of all primary data and they agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review their data.  相似文献
9.
BACKGROUND: This study examines the changes in short-term intraocular pressure (IOP) in patients receiving intravitreally administered bevacizumab. A prospective series of consecutive patients undergoing injection of intravitreal bevacizumab was investigated. METHODS: All patients received bevacizumab (0.05 cc) injected intravitreally in a standard fashion. IOP was measured at baseline, 2, 5, and 30 minutes after injection by 1 of 2 observers using Goldman applanation tonometry. An intraobserver study was done to assess agreement in IOP measurements. RESULTS: We accrued 104 patients with a mean age of 76 years: 58% were female, and 42% were male. Most patients (85%) were being treated for neovascular age-related macular degeneration. The mean IOP values at baseline, 2, 5, and 30 minutes after injection were 14.0 (95% confidence interval [CI] 13.4-14.7) mm Hg, 36.1 (95% CI 33.5-38.6) mm Hg, 25.7 (95% CI 23.8-27.5) mm Hg, and 15.5 (95% CI 12.4-16.51) mm Hg, respectively. Three patients (2.9%) had an IOP of 25 mm Hg or higher at 30 minutes. IOP normalized within 2 hours without medical therapy in 2 of these patients, and 1 patient required a 1-week course of glaucoma medication. Regression analysis showed a trend towards phakic patients having higher IOP at 30 minutes (odds ratio = 3.2; p = 0.089). INTERPRETATION: Intravitreal injection of bevacizumab is safe with respect to short-term IOP changes, as almost all patients' IOP returned to a safe range (<25 mm Hg) within 30 minutes. Elevated IOP at 30 minutes after injection does occur, rarely, thus clinicians should consider checking IOP after injection as a precaution. Transient extreme IOP elevations occur in a significant percentage of patients, but the consequences of these events are unknown.  相似文献
10.
Bevacizumab in retinal vein occlusion-results of a prospective case series   总被引:2,自引:0,他引:2  
Background Macular edema is the main reason for decreased visual acuity (VA) in early retinal vein occlusion (RVO). Bevacizumab (Avastin, Genentech) is an anti-VEGF substance to treat macular edema triggered by hypoxia-induced expression of vascular endothelial growth factor (VEGF). Initial reports showed a significant reduction of central retinal thickness and improved visual acuity (VA) after bevacizumab injection. To date, only retrospective studies and case reports have been published on bevacizumab treatment of RVO. Methods In this prospective interventional case series, we evaluated the response to a single bevacizumab treatment in 21 RVO patients (14 CRVO, 7 BRVO). Study endpoints were visual acuity (VA) using ETDRS charts and central macular edema (CME) over 9 weeks. Results Mean VA from all 21 patients increased by more than 2 lines (2.4±0.4 lines; p<0.01 compared to baseline). The improvement of VA after bevacizumab injection was concordant with a decrease in central retinal thickness. Peak VA was reached between 3 and 6 weeks after injection. Between week 6 and 9 a decrease in VA was observed. This VA decrease was precipitated by an increase in CME between week 3 and 6. In subgroup analyses, patients receiving bevacizumab injection within the first 3 months after RVO showed an average VA gain of 4 lines (range 2–7 lines) compared to an average gain of 1.8 (range 1–3) and 2.5 (range 1–7) in patients receiving bevacizumab between 4–6 months and after more than 6 months, respectively. Conclusions Bevacizumab injection is able to improve CME and VA in RVO patients within the first 3 to 9 weeks. We did not observe any short-term adverse effects during our study. As the decrease in VA was anticipated by an increase in central retinal thickness, regular OCT examinations between week 3 and 6 may be helpful for judging the appropriate timing for re-injection in order to maintain patients within the initially reached range of VA until a new balance between inflow and outflow in the retinal circulation is reached. None of the authors has financial relationships of any form with companies or organizations mentioned in the study.  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号